The primary objective of this study is to assess disease response to Doxil in patients with hormone refractory prostate cancer with or without dexamethasone pre-treatment.

Study Design:

We will perform an open labeled, parallel, randomized phase II study using a two-stage design to determine if there is sufficient anti-tumor activity in either arm to warrant further study. Assumptions made in this study: an unacceptable overall response rate is </= 10% & we will pursue further study if the overall response rate is >/= 30%. Fifteen patients will be randomized in the first phase (to both Arm 1 and Arm 2). No further patients will be accrued if <2/15 responses are noted in a given arm. Ten additional patients will be enrolled if >/= 2/15 responses are observed. If there are >/= 5/25 responses then further studies will be pursued with that regimen. We will determine the overall incidence & severity of toxicities in both arms.

Treatment:

Arm 1: Doxil: Dose: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Arm 2: Doxil: Dose: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Arm 1 only: Dexamethasone: Dose: 12 mg twice a day by mouth on days 1, 2, 3, 4, 5 of each 28 day cycle.

Number of Cycles for both Arm 1 & 2: until progression or unacceptable toxicity develops.

Condition	Intervention	Phase
Prostate Cancer	Drug: dexamethasone  Drug: doxorubicin	Phase II

Further Study Details: 

Primary Outcomes: •% subjects with CR or PR: evaluated after 2 courses then every other course.
Secondary Outcomes: • Hematologic toxicity: evaluated @ baseline & 3/wk during treatment or until recovery.; • % subjects with >/= Grade 3 hematopoietic & non-hematopoietic toxicities: labs evaluated @ baseline & 3/wk during treatment or until recovery; toxicity evaluated through treatment or until resolved.; • Clinical non-hematologic & hematologic toxicity: evaluate incidence of stomatitis, diarrhea, palmar plantar erythrodysesthesia, # hospital days febrile neutropenia, transfusions & bleeding, # days outpatient antibiotics -all assessed through study.; • Survival & QOL: QOL evaluated at baseline then every other cycle; survival evaluated through study.; • Fraction delivered vs. intended Doxil: evaluate each dose.; • cytokines: evaluated days 1, 5, 8 every other cycle.
Expected Total Enrollment:  50

Primary Objectives:

To assess the anti-tumor activity of Doxil by assessing response rates in patients with hormone refractory prostate cancer with or without dexamethasone pre-treatment.

Secondary Objectives:

To assess and estimate in patients with hormone refractory prostate cancer treated with Doxil with or without pre-treatment dexamethasone: 1) overall survival 2) toxicity, 3) quality of life parameters, 4) dose intensity administered in both treatment groups.

Study Design:

We will perform an open labeled, parallel, randomized phase II study using a two-stage design to determine if there is sufficient anti-tumor activity in either arm to warrant further study. Assumptions made in this study: an unacceptable overall response rate is </= 10% and we will pursue further study if the overall response rate is >/= 30%. The overall response rate for this study will be based on the total number of responses observed defined as: complete responses + partial responses (both by RECIST)+biochemical responses (in patients with no measurable target lesions a >/= 50% decrease in PSA for >/= 4 weeks). Fifteen patients will be randomized in the first phase (to both Arm 1 and Arm 2). No further patients will be accrued if <2/15 responses are noted in a given arm. Ten additional patients will be enrolled if >/= 2/15 responses are observed. If there are >/= 5/25 responses then further studies will be pursued with that regimen. We will determine the overall incidence and severity of toxicities in both arms.

Treatment:

Arm 1: Doxil: Dose: 50 mg/m2, IV. Frequency: day 5 of each 28 day cycle. Arm 2: Doxil: Dose: 50 mg/m2, IV. Frequency: day 5 of each 28 day cycle. Arm 1 only: Dexamethasone: Dose: 12 mg bid po. Frequency: days 1,2,3,4,5 of each 28 day cycle.

Number of Cycles for both Arm 1 and 2: until progression or unacceptable toxicity develops.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Male

Criteria

Inclusion Criteria:

1. Patients with metastatic hormone refractory prostate cancer as defined by resistance to both ablative therapy (with either LHRH agonists or orchiectomy) & anti-androgens.
2. Patients must have symptoms related to disease.
3. Patients must have PS 0,1,2 (ECOG).
4. Patients must have measurable disease (RECIST) or PSA > 5.
5. Patients must have adequate organ function as defined as follows: leukocytes >/= 3,000/mm3, absolute neutrophil count >/= 1,500/mm3, hemoglobin >/= 8.0g/dl, platelets >/= 100,000/mm3, serum creatinine </= 2.5 mg/dl. Bilirubin must be </= 2 fold above ULN. Liver transaminases (SGOT and/or SGPT) may be up to 2.5 x institutional ULN if alkaline phosphatase is </= ULN or alkaline phosphatase may be up to 4 x ULN if transaminases are </= ULN.
6. Patients must have a left ventricular ejection fraction (LVEF) 50% by echocardiogram
7. Patients must have failed to respond to discontinuation of anti-androgens.
8. No previous therapy with anti-androgens, corticosteroids or estrogens in the last 4 weeks.
9. Previous radiation therapy is allowed if completed at least 4 weeks prior to study entry & therapy was cumulatively administered to </= 25% of bone marrow.
10. Patients must be >18 years of age
11. Patients must have an expected survival of at least 4 months.
12. Patients must have the ability to understand & the willingness to sign a written informed consent document.
13. Patients must be willing to use adequate contraceptive method during treatment and for 3 months after completing treatment.

Exclusion Criteria:

1. Patients with previous history of cancer are excluded unless they have had curative treatment completed >/= 5 years prior to entry onto study or had 1 of the following: in situ carcinoma (any location), basal cell carcinoma, or non-metastatic squamous cell carcinoma of the skin.
2. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, uncontrolled diabetes mellitus, or psychiatric illness/social situations that would limit compliance with study requirements or the ability to provide informed consent.
3. Patients requiring any non study corticosteroids for any reason are excluded.
4. Patients who have received previous chemotherapy.
5. A history of cardiac disease with New York Heart Class II or greater, or clinical evidence of congestive heart failure.
6. Patients may not be receiving any other investigational agents or have participated in any investigational drug study within 4 weeks preceding initiation of treatment.
7. Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from major surgery.
8. Patients with a lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome or inability to swallow tablets.
9. History of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil®

Please refer to this study by ClinicalTrials.gov identifier  NCT00176293

Marynell Jenkins      859-257-3379    mhjenk2@email.uky.edu
Valorie Gray, CCRC      859-257-3379    valgray@email.uky.edu

Study chairs or principal investigators

John Rinehart, MD,  Principal Investigator,  University of Kentucky   

Study ID Numbers:  04-GU-52-B
Last Updated:  September 14, 2005
Record first received:  September 13, 2005
ClinicalTrials.gov Identifier:  NCT00176293
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-20